Montelukast for Postinfectious Cough
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02352545|
Recruitment Status : Unknown
Verified January 2015 by Liu Min, Beijing Chao Yang Hospital.
Recruitment status was: Recruiting
First Posted : February 2, 2015
Last Update Posted : February 2, 2015
|Condition or disease||Intervention/treatment||Phase|
|Cough||Drug: Montelukast||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Montelukast for Postinfectious Cough in Adults|
|Study Start Date :||August 2014|
|Estimated Primary Completion Date :||August 2015|
|Estimated Study Completion Date :||October 2015|
Experimental: Experimental: Montelukast
Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
Placebo Comparator: Placebo Comparator
Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
- Change in Leicester Cough Questionnaire(LCQ) total and domain scores at 10 days post randomisation [ Time Frame: 10 days ]
- cough visual analogue scale scores post randomisation(area under the curve) [ Time Frame: 10 days ]
- Change in Leicester Cough Questionnaire(LCQ) physical,psychological and social domain scores at 10 days post randomisation [ Time Frame: 10 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352545
|Contact: Kewu Huang, M.D.||firstname.lastname@example.org|
|Contact: Min Liu, Masteremail@example.com|
|China, Beijing, China, 100190|
|Contact: Kewu Huang, M.D. 86-10-85231167 firstname.lastname@example.org|
|Contact: Min Liu, Master 86-0-13522226189 email@example.com|
|Study Director:||Kewu Huang, M.D.||Beijing Chao Yang Hospital|